New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
18:35 EDTPNRA, TRN, TWTR, WB, YELP, FB, ICPT, BWLD, MOVE, AFL, AMGN, NCR, NUVA, ZLTQ, RUBI, RNG, ECYT, AEGR, EXAM, X, EW, SQNM, TXMDOn The Fly: After Hours Movers
UP AFTER EARNINGS: Panera Bread (PNRA), up 1.3%... Zeltiq Aesthetics (ZLTQ), up 28.1%... Rubicon Project (RUBI), up 12.5%... RingCentral (RNG), up 11%... Endocyte (ECYT), up 10.5%... Aegerion Pharmaceuticals (AEGR), up 9.4%... Examworks (EXAM), up 8.8%... U.S. Steel (X), up 7.3%... Edwards Lifesciences (EW), up 7.2%... Sequenom (SQNM), up 7.5%... NuVasive (NUVA), up 5.6%... NCR Corp. (NCR), up 3.5%... Amgen (AMGN), up 4% after reporting quarterly results and announcing that it will reduce its global workforce by 12%-15%... Trinity Industries (TRN), up 2.8%... Twitter (TWTR), up 29.1% after reporting better than expected second quarter results as well as third quarter and fiscal 2014 guidance above analyst expectations. NOTABLE: Weibo Corp (WB), up 5.5%; Yelp (YELP), up 3.6%; Facebook (FB), up just under 1%, respectively, following Twitter's second quarter results. ALSO HIGHER: Intercept Pharmaceuticals (ICPT), up 2.5% following upgrade to Buy from Neutral at Nomura. DOWN AFTER EARNINGS: Buffalo Wild Wings (BWLD), down 10.6%... Move Inc. (MOVE), down 3.5%... Aflac (AFL), down 4% after reporting second quarter results and guidance for third quarter and fiscal 2014. ALSO LOWER: TherapeuticsMD (TXMD), down marginally after filing to sell $40M in common stock.
News For PNRA;ZLTQ;RUBI;RNG;ECYT;AEGR;EXAM;X;EW;SQNM;NUVA;NCR;AMGN;TRN;TWTR;WB;YELP;FB;ICPT;BWLD;MOVE;AFL;TXMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | all recent news | >>
October 20, 2014
10:38 EDTNCRHigh option volume stocks
Subscribe for More Information
09:22 EDTNCROn The Fly: Pre-market Movers
Subscribe for More Information
07:24 EDTAEGRAegerion price target lowered to $46 from $66 at Leerink
Leerink lowered its price target for Aegerion shares to $46 after its survey of 40 U.S. cardiologists implied a more bearish outlook for Juxtapid once PCSK9s emerge. The firm, however, believes new patient adds are well outpacing Juxtapid discontinuations in the near term. It keeps an Outperform rating on the stock.
07:19 EDTAMGNIBC Life Sciences to hold a conference
Subscribe for More Information
07:13 EDTYELPYelp October weekly volatility elevated into Q3 and outlook
Subscribe for More Information
07:12 EDTNCRNCR Corp. sees FY14 NPOI $810M-$830M
In regards to FY14, says software-related revenue is expected to be $1.7B-$1.725B compared to previous guidance of $1.775B-$1.825B. Free cash flow, which includes the $93M Fox River environmental recovery, is expected to be approximately $225M-$275M versus our previous guidance of $250M-$300M.
07:10 EDTNCRNCR says restructuring program on track for $90M run-rate savings by 2016
Subscribe for More Information
07:03 EDTNCRNCR Corp. now sees FY14 EPS $2.60-$2.70, consensus $3.00
Subscribe for More Information
07:02 EDTNCRNCR Corp. expects Q3 free cash flow $132M
Subscribe for More Information
07:01 EDTNCRNCR Corp. expects Q3 EPS 67c, consensus 71c
Subscribe for More Information
October 19, 2014
15:56 EDTAMGNAmgen to aid in production method for Ebola drug ZMapp, Bloomberg says
Subscribe for More Information
October 17, 2014
16:01 EDTFB, TWTROptions Update; October 17, 2014
iPath S&P 500 VIX Short-Term Futures down 1.75 to 38.58 Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
12:17 EDTTWTRMark Cuban says buying Netflix shares, sees company as M&A target
Subscribe for More Information
09:38 EDTTWTRActive equity options trading on
Subscribe for More Information
09:06 EDTAMGNAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
08:48 EDTXBofA/Merrill global steel analysts hold analyst/industry conference call
Subscribe for More Information
October 16, 2014
16:44 EDTTWTRTwitter launches Audio Card with third-party streaming services
Subscribe for More Information
16:01 EDTTWTROptions Update; October 16, 2014
Subscribe for More Information
10:54 EDTTWTRTwitter October weekly volatility elevated into Q3 and growth outlook
Twitter October weekly call option implied volatility is at 94, November is at 75, December is at 58, January at 54; compared to its 26-week average of 54 according to Track Data, suggesting large near term price movement into the expected release of Q3 results after the market close on October 27.
09:39 EDTTWTR, FBActive equity options trading on open
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use